ArticleAntioxidants & redox signaling2011
Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.
Article in Antioxidants & redox signaling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 76 citations in OpenAlex.
- Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium.Schizophrenia research · 2019Trial
- Alteration pattern of serum albumin levels in schizophrenia from first episode through remission to relapse: a longitudinal study.Translational psychiatry · 2026Article
- Metabolic pathway modulation by olanzapine: Multitarget approach for treating violent aggression in patients with schizophrenia.World journal of psychiatry · 2025Article
- Review: Genes Involved in Mitochondrial Physiology Within 22q11.2 Deleted Region and Their Relevance to Schizophrenia.Schizophrenia bulletin · 2023Article
- Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship.Schizophrenia (Heidelberg, Germany) · 2022Article
- Diagnostic Performance of Increased Malondialdehyde Level and Oxidative Stress in Patients with Schizophrenia.Noro psikiyatri arsivi · 2021Article
- Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia.Brain sciences · 2020Review
- Metabolomic profiling on rat brain of prenatal malnutrition: implicated for oxidative stress and schizophrenia.Metabolic brain disease · 2019Article
- Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia.Cognitive neurodynamics · 2019Article
- Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients.Translational psychiatry · 2018Article
- Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases.Prostaglandins, leukotrienes, and essential fatty acids · 2018Review
- Oxidative Stress and the Central Nervous System.The Journal of pharmacology and experimental therapeutics · 2017Review
- Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia.PloS one · 2017Article
- Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia.Neuropsychiatric disease and treatment · 2016Article
- DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia.Open biology · 2015Article
- A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population.Journal of nutritional science · 2015Article
- Perineuronal nets and schizophrenia: the importance of neuronal coatings.Neuroscience and biobehavioral reviews · 2014Review
- Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.Schizophrenia bulletin · 2014Article
- Oxidative stress and psychological disorders.Current neuropharmacology · 2014Article
- Glucocorticoid regulates parkin expression in mouse frontal cortex: implications in schizophrenia.Current neuropharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Over a century, a wide-ranging variety of pathophysiological models and causal hypotheses have been conceptualized for schizophrenia. One among these is the role for free radical-mediated pathology in schizophrenia, indicating impaired antioxidant defense system (AODS) and presence of oxidative stress in patients with schizophrenia. For the past two decades, the whole investigative domain of AODS and oxidative stress has broadened to include the wider AODS components, direct central nervous system assays of AODS, chemical imaging studies, proteomics, genetics of AODS, and, of importance to sufferers of schizophrenia, antioxidant therapeutics. These are some of the perspectives that are reviewed by several articles in this Forum. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of schizophrenia and in treatment-related side effects. The totality of the evidence from biochemistry, metabolomics, proteomics, genetics, and in vivo brain imaging points to the presence of multifarious abnormalities in the AODS and redox signaling in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.